TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual…
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance…
Independent Study Shows Moderate Dose Strength of XORLO™ Attenuates Kidney ExpansionCALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics…
BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral…
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase…
Phase 2 clinical trial initiation expected in 2023Company to host conference call to discuss recent clinical updates, including updated data…
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company…
Oncology focused hospital to initiate Senhance System programRESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc.…
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacksParticipated…
Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host…